Please login to the form below

Not currently logged in
Email:
Password:

drug licensing

This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.

J&J exits $1.6bn blood cancer drug licensing deal with argenx

J&J exits $1.6bn blood cancer drug licensing deal with argenx

Johnson &Johnson (J&J) has pulled out of a $1.6bn licensing deal with Dutch biotech company argenx for the CD70-targeting antibody cusatuzumab. ... In December 2018, J&J and argenx signed a deal centred on cusatuzumab, to develop the drug for the

Latest news

  • Merck enters agreement with Hanmi for investigational NASH drug Merck enters agreement with Hanmi for investigational NASH drug

    NGM313 is an antibody targeting the beta-Klotho/FGFR1c receptor complex that could represent a new a completely new drug class for NASH and diabetes. ... The drug works by activating FGFR1c signalling, a pathway that appears to have a key role in

  • Moderna and GSK advance coronavirus vaccine candidates Moderna and GSK advance coronavirus vaccine candidates

    The drug was originally being developed as a treatment for the infectious diseases Ebola and Marbug virus. ... However, despite successfully copying and manufacturing the drug, BrightGene has said it will not launch the drug until it has received

  • China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

    However, Gilead which holds all patents around the development and production of the drug – including for its development as a treatment for coronavirus. ... Although BrightGene has said it has successfully developed and manufactured copies of the drug,

  • EU, US biotechs merge to create fibrosis, cancer player EU, US biotechs merge to create fibrosis, cancer player

    the new one has different ideas on how to pursue studies with this drug”. ... The US biotech had put the LOXL2 drug out for tender as a licensing candidate, and has also already hived off another research programme headed by autotaxin inhibitor PAT-409

  • Who's calling the shots in European healthcare? Who's calling the shots in European healthcare?

    In April, the EMA published a paper about added therapeutic benefits and drug licensing.it is now engaging with affordability arguments, so it can’t  bury its head in the sand ... Natsis believes that the rules of the game are changing, pointing to

More from news
Approximately 2 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... The most successful projects will validate strong genetic targets and will include licensing opportunities for leading drug target

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    first launched on the world drug market than major companies (those with R&D spend of US$2bn). ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • ‘Flexible working’: fashionable buzzword or fundamental business operation? ‘Flexible working’: fashionable buzzword or fundamental business operation?

    Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.

  • Charting a course for expansion Charting a course for expansion

    a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug

  • Pharma deals during January 2013 Pharma deals during January 2013

    Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...